Research programme: orally active thrombin inhibitors - Johnson & Johnson Pharmaceutical Research and Development, LLC/Centocor

Drug Profile

Research programme: orally active thrombin inhibitors - Johnson & Johnson Pharmaceutical Research and Development, LLC/Centocor

Alternative Names: JNJ 6368661; Orally active thrombin inhibitors research programme - 3-Dimensional Pharmaceuticals/Centocor

Latest Information Update: 11 Jul 2011

Price : $50

At a glance

  • Originator Johnson & Johnson Pharmaceutical Research & Development
  • Class
  • Mechanism of Action Thrombin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Thrombosis

Most Recent Events

  • 11 Jul 2011 Discontinued - Preclinical for Thrombosis in USA (PO)
  • 22 Dec 2003 Data presented at the 45th Annual Meeting of the American Society of Hematology (ASH-2003) have been added to the pharmacokinetics and Thrombosis pharmacodynamics sections
  • 16 Apr 2003 3-Dimensional Pharmaceuticals has been acquired by Johnson & Johnson
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top